Mobile

An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects with Chronic Hepatitis C Viru...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002925-36

An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy and safety of ABT-493 and ABT-530 with and without ribavirin (RBV) in subjects with chronic HCV genotype (GT) 1, 4, 5, and 6 infection with compensated cirrhosis (GT1 only) or without cirrhosis (all genotypes)

Critère d'inclusion

  • Chronic Hepatitis C Virus (HCV) Infection

Liens